Apgar, James M. published the artcileIbrexafungerp: An orally active β-1,3-glucan synthesis inhibitor, SDS of cas: 5034-06-0, the publication is Bioorganic & Medicinal Chemistry Letters (2021), 127661, database is CAplus and MEDLINE.
We previously reported medicinal chem. efforts that identified MK-5204 (I), an orally efficacious β-1,3-glucan synthesis inhibitor derived from the natural product enfumafungin. Further extensive optimization of the C2 triazole substituent identified 4-pyridyl as the preferred replacement for the carboxamide of MK-5204, leading to improvements in antifungal activity in the presence of serum, and increased oral exposure. Reoptimizing the aminoether at C3 in the presence of this newly discovered C2 substituent, confirmed that the (R) t-Bu, Me aminoether of MK-5204 provided the best balance of these two key parameters, culminating in the discovery of ibrexafungerp (II), which is currently in phase III clin. trials. Ibrexafungerp displayed significantly improved oral efficacy in murine infection models, making it a superior candidate for clin. development as an oral treatment for Candida and Aspergillus infections.
Bioorganic & Medicinal Chemistry Letters published new progress about 5034-06-0. 5034-06-0 belongs to chlorides-buliding-blocks, auxiliary class Salt,Aliphatic hydrocarbon chain, name is trimethyloxosulphonium chloride, and the molecular formula is C3H9ClOS, SDS of cas: 5034-06-0.
Referemce:
https://en.wikipedia.org/wiki/Chloride,
Chlorides – an overview | ScienceDirect Topics